Procore signs multi-year strategic collaboration agreement with AWS
NESS ZIONA, Israel—BiomX Inc. (NYSE American: PHGE), a biotechnology company specializing in biological products, announced significant corporate updates following its annual stockholder meeting held on Tuesday.
During the meeting, stockholders approved a series of proposals that will impact the company's governance and financial structure. Notably, the company received approval to increase the number of authorized shares of common stock from 120 million to 750 million. This change, effective as of Tuesday, is facilitated by an amendment to BiomX (NYSE:PHGE)'s certificate of incorporation.
Additionally, stockholders voted in favor of the amendment and restatement of the company's 2019 Omnibus Long-Term Incentive Plan (A&R 2019 LTIP), which also took effect on Tuesday. The A&R 2019 LTIP, described in detail in the Proxy Statement filed on June 17, 2024, is designed to provide long-term incentives to key personnel. The specifics of the A&R 2019 LTIP are outlined in the plan's full text, which was filed as an exhibit to the company's current report.
The annual meeting also saw the election of Alan Moses and Edward Williams as Class I directors to serve on the board until the 2027 Annual Meeting of Stockholders. Furthermore, stockholders approved the compensation of the company's named executive officers and decided that future advisory votes on executive compensation would occur every three years.
In another significant move, stockholders authorized the Board of Directors to implement a reverse stock split at a ratio between 1-for-5 and 1-for-10, at the board's discretion, anytime before July 9, 2025.
Finally, the company's choice of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified.
These decisions reflect the stockholders’ support for the company's strategic initiatives and provide a framework for future growth. The details of these corporate actions are based on the information provided in BiomX's SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.